What is Keppra?

This post was written with Consensus AI Academic Search Engine - please read our Disclaimer at the end of this article. Keppra, known generically as levetiracetam, is a second-generation antiepileptic drug (AED) widely used in the management of various types of seizures. It has gained popularity due to its unique mechanism of action, favorable pharmacokinetic profile, and broad-spectrum efficacy in seizure control.

Clinical Uses of Keppra

Keppra is approved for several indications:

• Adjunctive treatment of partial onset seizures: It is used in combination with other AEDs to manage partial onset seizures with or without secondary generalization9.

• Monotherapy for partial onset seizures: It is also approved as a standalone treatment for partial onset seizures9.

• Adjunctive treatment of myoclonic seizures: It is used in juvenile myoclonic epilepsy9.

• Primary generalized tonic-clonic seizures: It is effective in idiopathic generalized epilepsy9.

Pharmacokinetics

Levetiracetam is characterized by rapid and complete absorption, high oral bioavailability, and minimal metabolism. It is primarily eliminated through renal excretion and does not induce cytochrome P450 isoenzymes, minimizing the risk of drug-drug interactions9.

Efficacy and Safety

Numerous clinical trials have demonstrated the efficacy of levetiracetam in reducing seizure frequency. For instance, it has been shown to significantly improve seizure control in patients with refractory partial onset seizures when used as adjunctive therapy9. Additionally, it has been found to be noninferior to carbamazepine controlled release in newly diagnosed partial onset seizures4 9. Levetiracetam is generally well-tolerated, with most adverse events being mild to moderate. Common side effects include somnolence and behavioral changes, but it is not associated with cognitive impairment or weight gain9.

Special Considerations

Use in Palliative Care

Levetiracetam has been explored for managing seizures in palliative care settings. A combined analysis of 73 cases suggested that subcutaneous administration of levetiracetam could be beneficial in controlling seizures at the end of life, although randomized controlled trials are needed to confirm its efficacy and safety in this context2.

Post-Traumatic Brain Injury

Keppra has also been investigated for its role in preventing early onset post-traumatic seizures (PTS) in patients with traumatic brain injury (TBI). While some studies indicate a trend towards reduced seizure incidence with Keppra prophylaxis, the results have not reached statistical significance10.

Drug Interactions and Combination Therapy

Preclinical studies suggest that levetiracetam enhances the protective activity of other AEDs, particularly those that enhance GABAergic inhibition or reduce glutamatergic neurotransmission. This makes it a valuable option for combination therapy in drug-resistant epilepsy7. Learn more with Consensus: [button icon="💊" text="Is Keppra used as an adjunctive treatment for myoclonic seizures in juvenile myoclonic epilepsy?"][/button] [button icon="℞" text="Does Keppra have a favorable pharmacokinetic profile with minimal drug interactions?"][/button]

Keppra Mechanism of Action

Levetiracetam operates through a novel mechanism distinct from other AEDs. It binds to the synaptic vesicle protein 2A (SV2A), which is believed to modulate neurotransmitter release and synaptic transmission. This binding inhibits calcium release from intraneuronal stores and opposes the activity of negative modulators of GABA- and glycin-gated currents, thereby reducing excessive synchronized neuronal activity9. Learn more with Consensus: [button icon="🎡" text="What is Keppra mechanism of action?"][/button] [button icon="🍗" text="Does Keppra bind to synaptic vesicle protein 2A (SV2A)?"][/button]

Adverse Effects of Keppra

Common Adverse Effects Somnolence, asthenia, and dizziness are frequently reported, especially during the first month of treatment1 3 4. Headache and coordination difficulties are also common2 3 4. Behavioral and Neuropsychiatric Effects Mild neuropsychiatric symptoms such as apathy, agitation, anxiety, and depression have been observed2. Higher incidences of behavioral effects are noted among epilepsy patients compared to those with cognitive or anxiety disorders1. Infections Reports of infections (e.g., common cold, upper respiratory infections) are noted, although these are not linked to impaired immunological status1 4. Rare and Severe Adverse Effects Urinary retention is a rare but possible adverse effect, as highlighted in a case report2. Elevated levels of levetiracetam have been associated with suicidal drug deaths in postmortem studies5. Laboratory and Vital Signs Changes in laboratory test values (e.g., red blood cells, hematocrit, hemoglobin, white blood cells, and neutrophils) are statistically significant but remain within normal ranges1. No significant alterations in vital signs or laboratory parameters were observed in placebo-controlled trials3 4. Learn more with Consensus: [button icon="🌌" text="What are the adverse effects of Keppra?"][/button] [button icon="😵" text="Can Keppra cause somnolence and dizziness in patients?"][/button]

How has Keppra Improved Patient Outcomes?

Reduction in Levodopa-Induced Dyskinesias in Parkinson's Disease Keppra significantly increased the percentage of the day that Parkinson's disease patients spent without dyskinesia or with nontroublesome dyskinesia, improving their overall quality of life1. Management of Seizures in Palliative Care Subcutaneous administration of Keppra has been effective in managing seizures at the end of life, achieving therapeutic levels without significant site reactions. This suggests its potential role in palliative care settings2. Prophylaxis of Early Onset Post-Traumatic Seizures While Keppra showed a trend towards reducing the incidence of early-onset post-traumatic seizures in patients with traumatic brain injury, the reduction was not statistically significant. However, it may still offer some benefit, particularly in less severe cases3. Learn more with Consensus: [button icon="😒" text="How has Keppra improved patient outcomes?"][/button] [button icon="🛌" text="Can Keppra be administered subcutaneously to control seizures in palliative care patients?"][/button]

Disclaimer

The content presented in this blog is generated by Consensus, an AI-powered academic search engine, and is based on publicly available scientific literature. While every effort is made to provide accurate, up-to-date, and well-researched information, the content is intended for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any decisions regarding medical conditions, treatments, or medications. The AI system's analysis may not cover all perspectives, emerging research, or individual cases, and it is not a substitute for professional expertise. Neither the blog publisher nor the developers of the AI-powered search engine are responsible for any actions taken based on the information provided in this content. Use of this information is at your own risk. Citations to the original scientific studies are included for reference, but these studies should be reviewed in full and interpreted with the guidance of a healthcare or research professional. If you are experiencing a medical emergency, please seek immediate attention from a healthcare provider.